Abbott Resolves Litigation Over Preterm Infant Formula Claims and Stands By Safety Standards
Abbott Settles Legal Disputes Regarding Preterm Infant Formulas
In a significant development, Abbott, a leader in healthcare, has successfully negotiated agreements to resolve ongoing legal disputes related to its specialty formulas designed for preterm infants. This resolution addresses claims stemming from the Gill case and includes approximately 2,000 additional infant claims. The settlement involves an aggregate payment of about $670 million, representing both the Gill judgment and the claims from other affected families.
This legal conflict began acquiring momentum when a St. Louis jury awarded $495 million to the plaintiff in the Gill case in July 2024. Following an appeal that was ultimately denied in December 2024, Abbott faced a critical financial decision. Instead of enduring the lengthy appeals process and potentially paying $600 million, the company chose to pursue settlement agreements to bring closure to this contentious issue.
A Commitment to Safety
Despite these settlements, Abbott maintains a strong stance regarding the safety and importance of its preterm infant formulas. The FDA, NIH, and other health authorities have recognized these products as essential in neonatal care, stating there's no reliable evidence linking them to necrotizing enterocolitis (NEC), a serious intestinal disease affecting premature infants. Medical professionals— including neonatologists and members of the American Academy of Pediatrics— continue to support the use of these formulas, emphasizing they're a critical resource when human breast milk is unavailable.
In previous rulings, Abbott found affirmation in its safety claims during several federal and state court trials. Courts upheld the notion that the risk of NEC arises largely due to the absence of human milk rather than the use of formula. Recent favorable decisions in the U.S. Court of Appeals and various state courts further solidified this stance, showing a pattern of judicial support for manufacturers of preterm formulas.
Ongoing Legal Landscape
While Abbott’s recent agreements have resolved many claims, approximately 1,700 lawsuits concerning 12,700 individual infants still loom in the legal system, indicating an enduring battle for Abbott. These cases encompass claims arising from mixed usage of formulas and various medical histories, complicating the legal landscape for prematurity nutrition.
Advocates in the medical community have expressed concern regarding the implications of prolonged litigation on the availability of preterm formulas. The American Academy of Pediatrics has emphasized that litigation should not dictate feeding decisions, urging that they be made in clinical settings by healthcare professionals instead.
The Importance of Preterm Infant Formula
According to the CDC, about 1 in 10 infants born in the United States is premature. Not all parents can provide sufficient breast milk, making it essential for healthcare providers to have reliable access to specialized infant formulas. Judges in the federal MDL litigation have acknowledged that cow's-milk-based formulas, including Abbott’s Similac Special Care 24, remain critical for the health of premature infants until human milk production levels can meet the high demand in NICUs.
As Abbott moves forward, it aims to clarify and potentially reduce the number of pending cases while preserving the vital supply of infant formulas necessary for the care of vulnerable newborns. The company remains optimistic about its product's role in neonatal nutrition and is committed to supporting families and healthcare providers.
Conclusion
The agreements reached by Abbott reflect a strategic decision aimed at mitigating potential financial repercussions while reaffirming the company’s commitment to appropriately supporting the needs of preterm infants. In light of the medical community's ongoing endorsement, Abbott’s formulas continue to play a vital role in the healthcare landscape, underlining the importance of continued access to these essential products for the most vulnerable.
For more information about Abbott and its initiatives in neonatal care, visit Abbott's website
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.